Your Daily Biotechnology Briefing

Biotech Firms Attract Significant Capital for Autoimmune and Infectious Disease Therapies

• Deep Track Capital disclosed a new position in Alumis (ALMS), acquiring 6,772,595 shares valued at an estimated $169.31 million based on first-quarter average pricing, as reported on May 24, 2026. Alumis is advancing clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors, with recent Phase 3 psoriasis data showing PASI 90 response rates of 68.0% and 62.1% by Week 24.

  Fool

• Superstring Capital Management also established a new position in Vir Biotechnology (VIR), purchasing 730,548 shares with an estimated transaction value of $5.82 million in the first quarter, according to a May 23, 2026 filing. Vir Biotechnology focuses on developing immunology-based therapies to target infectious diseases through global partnerships and scientific innovation.

  Fool

• Artificial intelligence is increasingly embedded in pharmaceutical biotechnology, with machine learning tools routinely reducing early drug discovery timelines by approximately one-third by 2026, and preclinical candidate development dropping from four years to 13-18 months. This shift has led to a critical need for "scientific translators" who can navigate complex biology, regulatory requirements, and machine learning, with 67% of AI talent now sourced from internal upskilling rather than external tech hires.

  Futura SciencesDrugdiscoverynews